Colorectal Cancer
Conditions
Keywords
Huaier Granule, Colorectal Cancer, CEA Level, Negative Conversion Rate
Brief summary
This study is a prospective, observational and exploratory study to explore the effect of Huaier Granule on the negative conversion rate of patients with increased CEA levels after colorectal cancer surgery.
Detailed description
This study is a prospective, single center, observational study, expected to include patients who visited the selected research center from December 2022 to December 2024 and were pathologically diagnosed with stage I-III colorectal cancer and underwent R0 radical resection surgery. During routine clinical follow-up within one year after radical surgery, if serum CEA\>5.2ng/ml occurs, patients may choose whether to use Huaier granules to prevent recurrence and metastasis according to their wishes. Patients who agree to use Huaier granules will enter the observation group; Patients who do not agree to use it will enter the control group. After the subjects are enrolled, they will be visited every 1 month ± 7 days in the first year, and every 3 months ± 14 days starting from the second year according to clinical routine diagnosis and treatment, until imaging examination determines disease progression, the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, or the researcher determines no longer benefiting, whichever occurs first.
Interventions
DRUGHuaier granule
Oral administration, 10g per dose (1 bag), 3 times a day, recommended for at least 6 months.
Sponsors
Fudan University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥18 years old, gender not limited * Diagnosed with colorectal cancer through histopathology, pTNM stage I-III * Previously underwent radical resection for colorectal cancer, with a postoperative evaluation of R0 * Imaging did not detect recurrence or distant metastasis * Serum CEA\>5.2ng/ml within 1 year after surgery (found during routine clinical follow-up) * Clear consciousness, language expression or reading ability, able to communicate normally, and cooperate to complete the questionnaire evaluation * Voluntary participation in this study, good compliance, and signing of informed consent form.
Exclusion criteria
* Known to be allergic to the components of Huaier Granule, or to avoid or use Huaier Granule with caution (observation group) * Cannot take medicine orally * Have received anti-tumor traditional Chinese patent medicines and simple preparations treatment within 1 month before enrollment (subject to the instructions) * Combining medical history of other malignant tumors * Diabetes with serious heart, cerebrovascular and lung diseases, severe hypertension and poor blood sugar control * Suffering from intestinal diverticulitis, rectal polyps, colitis, pancreatitis, cirrhosis, hepatitis, etc * Currently participating in clinical trials of other drugs * Pregnant or lactating women or those planning to conceive * Refusing to cooperate with follow-up visits * Other reasons led the investigators to believe that it was not suitable to participate in this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of CEA conversion to negative | start of treatment until 2-year follow-up | The proportion of patients whose CEA levels returned to normal at each visit to the total number of patients at that follow-up. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 1 or 2-year disease-free survival rate (DFS) | start of treatment until 2-year follow-up | The proportion of surviving patients who did not experience imaging recurrence, distant metastasis, or death within 1 or 2 years after enrollment. |
| Quality of Life Score | baseline period and start of treatment until 2-year follow-up | Evaluation using the EORTC QLQ-C30 (Chinese version) core quality of life scale developed by the European Organization for Cancer Research and Treatment. |
Other
| Measure | Time frame | Description |
|---|---|---|
| The changes (rate values) of tumor markers (including but not limited to CA199, CA24-2, CA72-4, and CA50) compared to baseline | start of treatment until 2-year follow-up | The differences in tumor marker levels between treatment and baseline. |
Contacts
Primary ContactYe Xu, PhD
Outcome results
None listed